In Silico Assessment of Demethoxycurcumin: Molecular Docking and Computational Insights into its various therapeutic Potential

Year : 2024 | Volume :11 | Issue : 11 | Page : –
By

    Prosenjit Dutta

  1. Lata Khani Bisht

  2. Vineeth Chandy

  1. Research Scholar, T John College of Pharmacy, Karnataka, India
  2. Associate Professor, T John College of Pharmacy, Karnataka, India
  3. Principal, T John College of Pharmacy, Karnataka, India

Abstract

Natural compounds are increasingly explored for their therapeutic potential in medical research. Here, we focus on demethoxycurcumin (DMC), a polyphenolic bioactive compound extracted from Curcuma longa, commonly found in turmeric. DMC, with a chemical formula of C20H18O5 and molecular weight of 340 g/mol, possesses two aromatic ring systems, each featuring a β-diketone moiety connected by a seven-carbon chain. This unique structure allows DMC to engage in tautomerism, crucial for its biological effects and interactions with specific molecular targets.Our study investigates demethoxycurcumin’s potential for treating cancer, Alzheimer’s, inflammation, and COVID-19 SARS Omicron variant infection using molecular docking and computational techniques. Methodology involves utilizing the Pubchem and PDB databases to obtain DMC’s 3D structure and the target proteins’ crystal structures, respectively. Tools such as AutoDock 4.2 was employed to carry out molecular docking, Avogadro & BIOVIA Discovery Studio Visualizer used for ligand and protein preparations, and ChimeraX was employed for visualizing the molecular simulations. Molecular docking results exhibit promising affinities against cancer and Alzheimer’s, with robust binding to inflammation-related proteins indicating anti-inflammatory potential. Furthermore, DMC’s propensity to bind SARS-CoV-2 Omicron variant proteins suggests potential antiviral activity against COVID-19.Through molecular docking, we scrutinize DMC’s interactions with disease-associated targets, highlighting its distinct properties as a compelling natural compound for diverse drug development avenues. The insights gained lay the groundwork for future studies, delving into the medicinal chemistry of demethoxycurcumin and identifying its potential as a multi-targeted therapeutic agent. As drug discovery advances, this research offers crucial information for innovative therapy development across challenging diseases.Natural compounds are increasingly explored for their therapeutic potential in medical research. Here, we focus on demethoxycurcumin (DMC), a polyphenolic bioactive compound extracted from Curcuma longa, commonly found in turmeric. DMC, with a chemical formula of C20H18O5 and molecular weight of 340 g/mol, possesses two aromatic ring systems, each featuring a β-diketone moiety connected by a seven-carbon chain. This unique structure allows DMC to engage in tautomerism, crucial for its biological effects and interactions with specific molecular targets.Our study investigates demethoxycurcumin’s potential for treating cancer, Alzheimer’s, inflammation, and COVID-19 SARS Omicron variant infection using molecular docking and computational techniques. Methodology involves utilizing the Pubchem and PDB databases to obtain DMC’s 3D structure and the target proteins’ crystal structures, respectively. Tools such as AutoDock 4.2 was employed to carry out molecular docking, Avogadro & BIOVIA Discovery Studio Visualizer used for ligand and protein preparations, and ChimeraX was employed for visualizing the molecular simulations. Molecular docking results exhibit promising affinities against cancer and Alzheimer’s, with robust binding to inflammation-related proteins indicating anti-inflammatory potential. Furthermore, DMC’s propensity to bind SARS-CoV-2 Omicron variant proteins suggests potential antiviral activity against COVID-19.Through molecular docking, we scrutinize DMC’s interactions with disease-associated targets, highlighting its distinct properties as a compelling natural compound for diverse drug development avenues. The insights gained lay the groundwork for future studies, delving into the medicinal chemistry of demethoxycurcumin and identifying its potential as a multi-targeted therapeutic agent. As drug discovery advances, this research offers crucial information for innovative therapy development across challenging diseases.

Keywords: Demethoxycurcumin, Cancer, Alzheimer’s disease, Inflammatory Disorders, SARS-CoV-2 Omicron variant, Molecular Docking.

[This article belongs to Research & Reviews: A Journal of Drug Design & Discovery(rrjoddd)]

How to cite this article: Prosenjit Dutta, Lata Khani Bisht, Vineeth Chandy.In Silico Assessment of Demethoxycurcumin: Molecular Docking and Computational Insights into its various therapeutic Potential.Research & Reviews: A Journal of Drug Design & Discovery.2024; 11(11):-.
How to cite this URL: Prosenjit Dutta, Lata Khani Bisht, Vineeth Chandy , In Silico Assessment of Demethoxycurcumin: Molecular Docking and Computational Insights into its various therapeutic Potential rrjoddd 2024 {cited 2024 Apr 15};11:-. Available from: https://journals.stmjournals.com/rrjoddd/article=2024/view=143322


Browse Figures

References

1. Wilson B, Abraham G, Manju VS, Mathew M, Vimala B, Sundaresan S, et al. Antimicrobial activity of Curcuma zedoaria and Curcuma malabarica tubers. J Ethnopharmacol. 2005;99:147–151.
2. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.
3. Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M, et al. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: A randomized controlled trial. Inflammopharmacology. 2017;25:25–31.
4. Sahebkar A, Serban MC, Ursoniu S, Banach M. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. J Funct Foods. 2015;18:898–909.
5. Karimian MS, Pirro M, Majeed M, Sahebkar A. Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev. 2017;33:55–63.
6. Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial. Clin Nutr. 2015;34:1101–1108.
7. Sahebkar A, Cicero AFG, Simental-Mendía LE, Aggarwal BB, Gupta SC. Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016;107:234–242
8. Momtazi AA, Sahebkar A. Difluorinated curcumin: A promising curcumin analogue with improved antitumor activity and pharmacokinetic profile. Curr Pharm Des. 2016;22:4386–4397.
9. Teymouri M, Pirro M, Johnston TP, Sahebkar A. Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features. BioFactors. 2017;43:331–346.
10. Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M, et al. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: A randomized controlled trial. Inflammopharmacology. 2017;25:25–31.
11. Panahi Y, Khalili N, Sahebi E, Namazi S, Simental-Mendía LE, Majeed M, et al. Effects of curcuminoids plus piperine on glycemic, hepatic, and inflammatory biomarkers in patients with type 2 diabetes mellitus: A randomized double-blind placebo-controlled trial. Drug Res. 2018;68:403–409.
12. Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes, and neurodegenerative disease: A recent update. Food Chem Toxicol. 2015;83:111–124.
13. Monroy A, Lithgow GJ, Alavez S. Curcumin and neurodegenerative diseases. Biofactors. 2013;39:122–132
14. Saeidinia A, Keihanian F, Butler AE, Bagheri RK, Atkin SL, Sahebkar A. Curcumin in heart failure: A choice for complementary therapy? Pharmacol Res. 2018;131:112–119.
15. Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcuminoids–piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complementary therapies in medicine. 2014 Oct 1;22(5):851-7.
16. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: A randomized double‐blind placebo‐controlled trial. Phytotherapy research. 2014 Nov;28(11):1625-31.
17. Abdollahi E, Momtazi AA, Johnston TP, Sahebkar A. Therapeutic effects of curcumin in inflammatory and immune‐mediated diseases: A nature‐made jack‐of‐all‐trades?. Journal of cellular physiology. 2018 Feb;233(2):830-48.
18. Lelli D, Sahebkar A, Johnston TP, Pedone C. Curcumin use in pulmonary diseases: State of the art and future perspectives. Pharmacol Res. 2017;115:133–148.
19. Keihanian F, Saeidinia A, Bagheri RK, Johnston TP, Sahebkar A. Curcumin, hemostasis, thrombosis, and coagulation. Journal of cellular physiology. 2018 Jun;233(6):4497-511.
20. Hatamipour M, Ramezani M, Tabassi SAS, Johnston TP, Ramezani M, Sahebkar A. Demethoxycurcumin: A naturally occurring curcumin analogue with antitumor properties. J Cell Physiol. 2018;233(12):9247–9260.
21. Morris GM et al. J Computational Chemistry. 1998 19: 1639
22. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. and Olson, A. J. (2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. Computational Chemistry 2009, 16: 2785-91.
23. UCSF ChimeraX: Tools for structure building and analysis. Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, Ferrin TE. Protein Sci. 2023 Nov;32(11):e4792.
24. A. Daina, O. Michielin, V. Zoete. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017; 7:42717. doi: 10.1038/srep42717.

Regular Issue Subscription Original Research
Volume 11
Issue 11
Received March 14, 2024
Accepted April 4, 2024
Published April 15, 2024
Views: 22